Neuronetics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US64131A1051
USD
1.45
0.22 (18.37%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Delcath Systems, Inc.
Akili, Inc.
Neuronetics, Inc.
Eargo, Inc.
ReWalk Robotics Ltd.
Sonendo, Inc.
IRIDEX Corp.
Sensus Healthcare, Inc.
DermTech, Inc.
Meihua International Medical Technologies Co., Ltd.
Daxor Corp.

Why is Neuronetics, Inc. ?

1
Poor long term growth as Operating profit has grown by an annual rate -5.77% of over the last 5 years
2
With a growth in Net Sales of 85.73%, the company declared Very Positive results in Sep 25
  • The company has declared positive results in Jan 70 after 4 consecutive negative quarters
  • NET PROFIT(HY) Higher at USD -19.16 MM
  • NET SALES(Q) At USD 37.3 MM has Grown at 101.28%
  • INVENTORY TURNOVER RATIO(HY) Highest at 14.55 times
3
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of -70.65%, its profits have fallen by -37.8%
4
Rising Promoter Confidence
  • Promoters have increased their stake in the company by 27.94% over the previous quarter and currently hold 27.94% of the company
  • Promoters increasing their stake is a sign of high confidence in the future of the business
5
Underperformed the market in the last 1 year
  • Even though the market (S&P 500) has generated returns of 14.90% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -70.65% returns
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Neuronetics, Inc. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Neuronetics, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Neuronetics, Inc.
-70.65%
-0.32
89.27%
S&P 500
14.9%
0.77
19.29%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
20.55%
EBIT Growth (5y)
-5.77%
EBIT to Interest (avg)
-6.07
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.10
Sales to Capital Employed (avg)
0.99
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
52.24%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.40
EV to EBIT
-3.47
EV to EBITDA
-3.79
EV to Capital Employed
2.03
EV to Sales
1.00
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-58.38%
ROE (Latest)
-161.16%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bearish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

18What is working for the Company
NET PROFIT(HY)

Higher at USD -19.16 MM

NET SALES(Q)

At USD 37.3 MM has Grown at 101.28%

INVENTORY TURNOVER RATIO(HY)

Highest at 14.55 times

DEBTORS TURNOVER RATIO(HY)

Highest at 6.75 times

OPERATING PROFIT(Q)

Highest at USD -6.43 MM

OPERATING PROFIT MARGIN(Q)

Highest at -17.25 %

EPS(Q)

Highest at USD -0.13

-7What is not working for the Company
ROCE(HY)

Lowest at -239.53%

RAW MATERIAL COST(Y)

Grown by 40.82% (YoY

CASH AND EQV(HY)

Lowest at USD 52.29 MM

INTEREST(Q)

Highest at USD 2.21 MM

Here's what is working for Neuronetics, Inc.

Net Sales
At USD 37.3 MM has Grown at 101.28%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very positive

Net Sales (USD MM)

Net Profit
Higher at USD -19.16 MM
than preceding 12 month period ended Sep 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Operating Profit
Highest at USD -6.43 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin
Highest at -17.25 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

EPS
Highest at USD -0.13
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Inventory Turnover Ratio
Highest at 14.55 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio
Highest at 6.75 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Here's what is not working for Neuronetics, Inc.

Interest
At USD 2.21 MM has Grown at 12.04%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Interest
Highest at USD 2.21 MM
in the last five periods and Increased by 12.04% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Cash and Eqv
Lowest at USD 52.29 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Raw Material Cost
Grown by 40.82% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales